DDInter915 DDInter1658
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Indacaterol {u} (Compound) resembles {v} (Compound) Procaterol
Indacaterol {u} (Compound) treats {v} (Disease) asthma
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Indacaterol (Compound) resembles Procaterol (Compound)
Indacaterol (Compound) treats asthma (Disease)
Indacaterol (Compound) binds ADRB1 (Gene)
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Indacaterol (Compound) causes Cardiac disorder (Side Effect)